

I hereby certify that this paper is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 596704395 US, on the date shown below in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


Dated: July 30, 2007

Signature:

(Lori Sims)

Patent

Docket No. 252312007900



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Vibeke STRAND et al.

Serial No.: 10/748,541

Filing Date: December 29, 2003

For: METHODS OF IMPROVING HEALTH-
RELATED QUALITY OF LIFE IN
INDIVIDUALS WITH SYSTEMIC
LUPUS ERYTHEMATOSUS

Examiner: G. Ewoldt

Group Art Unit: 1644

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of foreign documents and non-patent literature are submitted herewith. The Examiner is requested to make these documents of record.

This Supplemental Information Disclosure Statement is submitted:

- With the application; accordingly, no fee or separate requirements are required.
- Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.

- Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - A fee is required. A check in the amount of __ is enclosed.
 - A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is believed to be due.
- After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of __ is enclosed.
 - A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petition and/or other


Application Serial No. 10/748,541

Patent
Docket No. 252312007900

fees due in connection with the filing of this document to **Deposit Account No. 03-1952**
referencing 252312007900.

Dated: July 30, 2007

Respectfully submitted,

By 
Alicia J. Hager
Registration No.: 44,140

MORRISON & FOERSTER LLP
755 Page Mill Road
Palo Alto, California 94304-1018
(650) 813-4296



ALTERNATIVE TO PTO/SB/08A/B (04/07)

Substitute for form 1449/PTO				Complete if Known	
				Application Number	10/748,541
				Filing Date	December 29, 2003
				First Named Inventor	Vibeke STRAND
				Art Unit	1644
				Examiner Name	G. Ewoldt
Sheet	1	of	5	Attorney Docket Number	252312007900

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ³ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
1.	US-2003/0077273-A1	04-24-2003	Linnik et al.		
2.	US-2004/0224366-A1	11-11-2004	Jones et al.		
3.	US-2005/0004351-A1	01-06-2005	Marquis et al.		
4.	US-2005/0026856-A1	02-03-2005	Coutts et al.		
5.	US-2005/0031635-A1	02-10-2005	Coutts et al.		
6.	US-2005/0175620-A1	08-11-2005	Jones		
7.	US-2005/0208480-A1	09-22-2005	Victoria et al.		
8.	US-2005/0220785-A1	10-06-2005	Engle et al.		
9.	US-2005/0226844-A1	10-13-2005	Jones		
10.	US-2006/0142229-A1	06-29-2006	Linnik et al.		
11.	US-2006/0217333-A1	09-28-2006	Linnik et al.		
12.	US-2006/0229270-A1	10-12-2006	Linnik		
13.	US-6,858,210-B1	02-22-2005	Marquis et al.		
14.	US-6,951,939-B2	10-04-2005	Jones		
15.	US-7,081,242-B1	07-25-2006	Linnik et al.		
16.	US-7,138,244-B2	11-21-2006	Barstad et al.		

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ³ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	17.	EP-0 743 856-B1	11-27-1996	The University of Virginia Patent Foundation	
	18.	WO-92/05801-A1	04-16-1992	University of Virginia Patents Foundation	
	19.	WO-00/15259-A1	03-23-2000	The University of Virginia Patent Foundation	

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	20.	Aharoni, A. et al., (1993) "Characterization of a Multisubunit Human Protein Which Selectively Binds Single Stranded d(GA) _n and d(GT) _n Sequence Repeats in DNA" <i>Nucl. Acid. Res.</i> 21(22):5221-5228.			
	21.	Ferguson, P. J. et al. (July 1, 1995). "Antigen-Based Heteropolymers Facilitate, Via Primate Erythrocyte Complement Receptor Type 1, Rapid Erythrocyte Binding of an Autoantibody and Its Clearance From The Circulation in Rhesus Monkeys," <i>The Journal of Immunology</i> 155(1):339-347.			
	22.	Food and Drug Administration. (October 13, 2004). Information from United States Food and Drug Administration, 2 pages.			

Examiner Signature	Date Considered
--------------------	-----------------

Substitute for form 1449/PTO				Complete if Known	
				Application Number	10/748,541
				Filing Date	December 29, 2003
				First Named Inventor	Vibeke STRAND
				Art Unit	1644
				Examiner Name	G. Ewoldt
Sheet	2	of	5	Attorney Docket Number	252312007900

23.	Iverson, G.M. et al. (December 1998). "Anti- β_2 glycoprotein I (β 2GPI) Autoantibodies Recognize an Epitope on the First Domain of β 2GPI" <i>Proc Natl Acad Sci USA</i> 95:15542-15546.	
24.	Iverson, G.M. et al. (1998). "A Chemically Defined, Toleragen-Based Approach for Targeting Anti- β_2 -glycoprotein I Antibodies" <i>Lupus</i> 7 (Suppl 2): S166-S169.	
25.	Jones, D. et al. (1998) "Synthesis of a Cyclic-Thioether Peptide Which Binds Anti-Cardiolipin Antibodies" <i>Tetrahedron Letters</i> 39:6107-6110.	
26.	Jones, D. et al. (1999). "Multivalent Thioether-Peptide Conjugates: B Cell Tolerance of an Anti-Peptide Immune Response" <i>Bioconjugate Chemistry</i> 10(3):480-488.	
27.	Jones, D. et al. (2000). "A Convenient Synthesis of N-(tert-butyloxycarbonyl) Aminoxy Ethers," <i>Tetrahedron Letters</i> 41: 1531-1533.	
28.	Jones, D.S. et al. (1994). "A New Oligonucleotide Conjugate for Suppression of Anti-Double Stranded DNA Antibodies," <i>Abstracts of Papers</i> , Part 1, 207 th American Chemical Society National Meeting, San Diego, CA March 13-17, 1994, Abstract No. BIOT 113.	
29.	Kandiah, D.A. et al. (1998) "Current Insights into the "Antiphospholipid" Syndrome: Clinical, Immunological, and Molecular Aspects," <i>Advances in Immunology</i> 70:507-563.	
30.	La Jolla Pharmaceutical Co. (February 16, 2004). "La Jolla Pharmaceutical's New Drug Application for Lupus Drug Candidate Riquent® Accepted for Review by FDA," located at < http://web.archive.org/web/20040919061150/www.prnewswire.com/cgi-bin/stories.pl?ACCT=105&ST... >, last visited on March 26, 2007, 2 pages.	
31.	La Jolla Pharmaceutical Co. (February 17, 2004). "La Jolla Pharmaceutical's New Drug Application for Lupus Drug Candidate Riquent® Accepted for Review by FDA San Diego," located at < http://www.ljpc.com/pressrelease/0217_04.html >, last visited on April 9, 2007, 2 pages.	
32.	La Jolla Pharmaceutical Co. (March 2, 2004). "La Jolla Pharmaceutical Company Reports Fourth Quarter and Year End 2003 Financial Results," located at < http://www.ljpc.com/pressrelease/0302_04.html >, last visited on April 9, 2007, 3 pages.	
33.	La Jolla Pharmaceutical Co. (March 11, 2004). "La Jolla Pharmaceutical to Present Additional Riquent® Results at SG Cowen Healthcare Conference," located at < http://www.ljpc.com/pressrelease/0311_04.html >, last visited on April 9, 2007, 3 pages.	
34.	La Jolla Pharmaceutical Co. (April 21, 2004). "La Jolla Pharmaceutical to Present at 7 th International Congress on Systemic Lupus Erythematosus and Related Conditions," located at < http://www.ljpc.com/pressrelease/0421_04.html >, last visited on April 9, 2007, 3 pages.	
35.	La Jolla Pharmaceutical Co. (May 6, 2004). "La Jolla Pharmaceutical Company Reports First Quarter 2004 Financial Results," located at < http://www.ljpc.com/pressrelease/0506_04.html >, last visited on April 9, 2007, 2 pages.	
36.	La Jolla Pharmaceutical Co. (May 10, 2004). "La Jolla Pharmaceutical Data on Riquent® Presented at Lupus Medical Conference," located at < http://www.ljpc.com/pressrelease/0510_04.html >, last visited on April 9, 2007, 3 pages.	
37.	La Jolla Pharmaceutical Co. (June 10, 2004). "La Jolla Pharmaceutical Presents at European Rheumatology Medical Conference," located at < http://www.ljpc.com/pressrelease/0610_04.html >, last visited on April 9, 2007, 2 pages.	
38.	La Jolla Pharmaceutical Co. (June 24, 2004). "La Jolla Pharmaceutical Announces Publication of Review Articles Regarding Its Two Drug Candidates," located at < http://www.ljpc.com/pressrelease/0624_04.html >, last visited on April 9, 2007, 3 pages.	

Examiner Signature		Date Considered
--------------------	--	-----------------

Substitute for form 1449/PTO				Complete if Known	
				Application Number	10/748,541
				Filing Date	December 29, 2003
				First Named Inventor	Vibeke STRAND
				Art Unit	1644
				Examiner Name	G. Ewoldt
Sheet	3	of	5	Attorney Docket Number	252312007900

	39.	La Jolla Pharmaceutical Co. (August 2, 2004). "La Jolla Pharmaceutical Reaches Agreement with Cardio-Renal Division of FDA Regarding Phase 4 Trial Design Under Special Protocol Assessment," San Diego, CA, located at < http://www.ljpc.com/pressrelease/0802_04.html >, last visited on April 9, 2007, 3 pages.	
	40.	La Jolla Pharmaceutical Co. (August 5, 2004). "La Jolla Pharmaceutical Company Reports Second Quarter 2004 Financial Results," located at < http://www.ljpc.com/pressrelease/0805_04.html >, last visited on April 9, 2007, 2 pages.	
	41.	La Jolla Pharmaceutical Co. (October 14, 2004). "La Jolla Pharmaceutical Company Receives Letter From FDA About Riquent," located at < http://www.ljpc.com/pressrelease/1014_04.html >, last visited on April 9, 2007, 2 pages.	
	42.	La Jolla Pharmaceutical Co. (October 29, 2004). "La Jolla Pharmaceutical Company Presents at American College of Rheumatology and American Society of Nephrology Annual Meetings," located at < http://www.ljpc.com/pressrelease/1029_04.html >, last visited on April 9, 2007, 3 pages.	
	43.	La Jolla Pharmaceutical Co. (November 4, 2004). "La Jolla Pharmaceutical Company Reports Third Quarter 2004 Financial Results," located at < http://www.ljpc.com/pressrelease/1104_04.html >, last visited on April 9, 2007, 2 pages.	
	44.	La Jolla Pharmaceutical Co. (November 23, 2004). "La Jolla Pharmaceutical Company Provides Update on Riquent Program," San Diego, CA, located at < http://www.ljpc.com/pressrelease/1123_04.html >, last visited on April 9, 2007, 3 pages.	
	45.	La Jolla Pharmaceutical Co. (February 17, 2005). "La Jolla Pharmaceutical Company Presents at BIO CEO & Investor Conference," located at < http://www.ljpc.com/pressrelease/0217_05.html >, last visited on April 9, 2007, 2 pages.	
	46.	La Jolla Pharmaceutical Co. (March 3, 2005). "La Jolla Pharmaceutical Company Reports Fourth Quarter and Year End 2004 Financial Results," located at < http://www.ljpc.com/pressrelease/0303_05.html >, last visited on April 9, 2007, 2 pages.	
	47.	La Jolla Pharmaceutical Co. (March 14, 2005). "La Jolla Pharmaceutical Announces Outcome of Recent FDA Discussions," San Diego, CA, located at < http://www.ljpc.com/pressrelease/0314_05.html >, last visited on April 9, 2007, 2 pages.	
	48.	La Jolla Pharmaceutical Co. (March 30, 2005). "La Jolla Pharmaceutical Restructures Following Recent FDA Discussion," located at < http://www.ljpc.com/pressrelease/0330_05.html >, last visited on April 9, 2007, 3 pages.	
	49.	La Jolla Pharmaceutical Co. (May 5, 2005). "La Jolla Pharmaceutical Company Reports First Quarter 2005 Financial Results," located at < http://www.ljpc.com/pressrelease/0505_05.html >, last visited on April 9, 2007, 3 pages.	
	50.	La Jolla Pharmaceutical Co. (May 31, 2005). "La Jolla Pharmaceutical Company Provides Update on Riquent," located at < http://www.ljpc.com/pressrelease/0531_05.html >, last visited on April 9, 2007, 2 pages.	
	51.	La Jolla Pharmaceutical Co. (August 4, 2005). "La Jolla Pharmaceutical Company Reports Second Quarter and Year-to-Date 2005 Financial Results," located at < http://www.ljpc.com/pressrelease/0804_05.html >, last visited on April 9, 2007, 3 pages.	
	52.	La Jolla Pharmaceutical Co. (October 13, 2005). "La Jolla Pharmaceutical Company to Present at BIO Investor Forum 2005," located at < http://www.ljpc.com/pressrelease/1013_05.html >, last visited on April 9, 2007, 2 pages.	
	53.	La Jolla Pharmaceutical Co. (October 18, 2005). "La Jolla Pharmaceutical Company Provides Update on Riquent®," located at < http://www.ljpc.com/pressrelease/1018_05.html >, last visited on April 9, 2007, 4 pages.	
	54.	La Jolla Pharmaceutical Co. (November 2, 2005). "La Jolla Pharmaceutical Company Presents at the Rodman & Renshaw Techvest 7 th Annual Healthcare Conference," located at < http://www.ljpc.com/pressrelease/1102_05.html >, last visited on April 9, 2007, 2 pages.	
	55.	La Jolla Pharmaceutical Co. (November 14, 2005). "La Jolla Pharmaceutical Company	

Examiner Signature	Date Considered
--------------------	-----------------

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
Sheet	4	of	5	Application Number	10/748,541
				Filing Date	December 29, 2003
				First Named Inventor	Vibeke STRAND
				Art Unit	1644
				Examiner Name	G. Ewoldt
				Attorney Docket Number	252312007900

		Presents at American College of Rheumatology Annual Scientific Meeting," located at <http://www.ljpc.com/pressrelease/1114_05.html>, last visited on April 9, 2007, 3 pages.	
	56.	La Jolla Pharmaceutical Co. (January 11, 2006). "La Jolla Pharmaceutical Company to Initiate Multi-Dose Study of Riquent in Lupus Patients," located at <http://www.ljpc.com/pressrelease/0111_06.html>, last visited on April 10, 2007, 2 pages.	
	57.	La Jolla Pharmaceutical Co. (March 29, 2006). "La Jolla Pharmaceutical Company Presents at National Autoimmune Disease Conference," located at <http://www.ljpc.com/pressrelease/0329_06.html>, last visited on April 10, 2007, 2 pages.	
	58.	La Jolla Pharmaceutical Co. (June 22, 2006). "La Jolla Pharmaceutical Company Files Marketing Authorization Application for European Regulatory Approval of Riquent," located at <http://www.ljpc.com/pressrelease/0622_06.html>, last visited on April 9, 2007, 3 pages.	
	59.	La Jolla Pharmaceutical Co. (August 9, 2006). "La Jolla Pharmaceutical Expands Enrollment in Phase 3 International Riquent® Study," located at <http://www.ljpc.com/pressrelease/0809_06.html>, last visited on April 9, 2007, 4 pages.	
	60.	La Jolla Pharmaceutical Co. (September 27, 2006). "La Jolla Pharmaceutical Provides Update on Phase 3 International Riquent® Study," located at <http://www.ljpc.com/pressrelease/0927_06.html>, last visited on April 9, 2007, 3 pages.	
	61.	La Jolla Pharmaceutical Co. (October 12, 2006). "La Jolla Pharmaceutical Provides Update on MAA Application in Europe," located at <http://www.ljpc.com/pressrelease/1012_06.html>, last visited on April 9, 2007, 3 pages.	
	62.	La Jolla Pharmaceutical Co. (November 6, 2006). "La Jolla Pharmaceutical Announces Continued Progress With Phase 3 International Riquent® Study," located at <http://www.ljpc.com/pressrelease/1106_06.html>, last visited on April 9, 2007, 3 pages.	
	63.	La Jolla Pharmaceutical Co. (February 1, 2007). "La Jolla Pharmaceutical Announces Continued Enrollment Progress and Enhancements to International Phase 3 Riquent® Study," located at <http://www.ljpc.com/pressrelease/0201_07.html>, last visited on April 9, 2007, 3 pages.	
	64.	La Jolla Pharmaceutical Co. (March 8, 2007). "La Jolla Pharmaceutical Announces Positive Interim Antibody Results From Riquent® Lupus Phase 3 Trial," located at <http://www.ljpc.com/pressrelease/0308_07.html>, last visited on April 9, 2007, 4 pages.	
	65.	La Jolla Pharmaceutical Co. (March 20, 2007). "La Jolla Pharmaceutical Announces Positive Interim Antibody Results From Riquent® Lupus Phase 3 Trial," located at <http://www.ljpc.com/pressrelease/0320_07_phase_3_results.html>, last visited on April 9, 2007, 3 pages.	
	66.	Linnik, M.D. et al. (2004). "Anti-dsDNA Antibodies and Exacerbation of Renal Disease in Patients with Systemic Lupus Erythematosus: Results From 2 Randomized Controlled Trials [RCTS] with LJP 394," located at <http://www.ljpc.com/abstracts/abstract_2004_15.html>, last visited on August 19, 2005, 2 pages.	
	67.	Linnik, M.D. et al. (2005). "Progressive Reduction in Risk of Renal Flare in SLE Patients is Associated With Improved Long-term Control of Anti-dsDNA Antibody Levels," located at <http://www.ljpc.com/abstracts/abstract_2005_05.html>, last visited July 29, 2007, 2 pages.	
	68.	Linnik, M.D. et al. (April 2005). "Relationship Between Anti-Double-Stranded DNA Antibodies and Exacerbation of Renal Disease in Patients With Systemic Lupus Erythematosus," <i>Arthritis & Rheumatism</i> 52(4):1129-1137.	

Examiner Signature		Date Considered
--------------------	--	-----------------


Substitute for form 1449/PTO				<i>Complete if Known</i>	
				Application Number	10/748,541
				Filing Date	December 29, 2003
				First Named Inventor	Vibeke STRAND
				Art Unit	1644
				Examiner Name	G. Ewoldt
Sheet	5	of	5	Attorney Docket Number	252312007900

69.	Morimoto, C. et al. (March 1987). "A Defect of Immunoregulatory T Cell Subsets in Systemic Lupus Erythematosus Patients Demonstrated with Anti-2H4 Antibody," <i>J Clin Invest.</i> 79(3):762-768.	
70.	Office Action mailed on February 22, 2005 for U.S. Patent Application No. 10/219,238, 13 pages.	
71.	Office Action mailed on February 26, 2007 for U.S. Patent Application No. 10/814,555, 9 pages.	
72.	Office Action mailed on January 14, 2005 for U.S. Patent Application No. 10/144,391, 11 pages.	
73.	Office Action mailed on July 18, 2000 for U.S. Patent Application No. 09/457,875, 7 pages.	
74.	Office Action mailed on October 5, 2001 for U.S. Patent Application No. 09/766,365, 5 pages.	
75.	PDRhealth. (Date Unknown). "Lupus Erythematosus," located at < http://www.pdrhealth.com/patient_education/BHG01RH18.shtml >, last visited July 11, 2007, 8 pages.	
76.	Sem, D.S. et al. (1998). "Structural Characterization and Optimization of Antibody-Selected Phage Library Mimotopes of an Antigen Associated with Autoimmune Recurrent Thrombosis," <i>Biochemistry</i> 37(46):16069-16081.	
77.	United States Application No. 09/590,592 filed on June 8, 2000 for Jones et al.	
78.	United States Application No. 11/562,174 filed on November 21, 2006 for Strand et al.	
79.	United States Application No. 11/565,467 filed on November 30, 2006 for Linnik et al.	
80.	United States Application No. 11/613,987 filed on December 20, 2006 for Linnik.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Date Considered
--------------------	-----------------



COPY

ALTERNATIVE TO PTO/SB/08A/B (04/07)

Substitute for form 1478 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
Sheet	1	of	5	Application Number	10/748,541
				Filing Date	December 29, 2003
				First Named Inventor	Vibeke STRAND
				Art Unit	1644
				Examiner Name	G. Ewoldt
				Attorney Docket Number	252312007900

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
1.	US-2003/0077273-A1	04-24-2003	Linnik et al.		
2.	US-2004/0224366-A1	11-11-2004	Jones et al.		
3.	US-2005/0004351-A1	01-06-2005	Marquis et al.		
4.	US-2005/0026856-A1	02-03-2005	Coutts et al.		
5.	US-2005/0031635-A1	02-10-2005	Coutts et al.		
6.	US-2005/0175620-A1	08-11-2005	Jones		
7.	US-2005/0208480-A1	09-22-2005	Victoria et al.		
8.	US-2005/0220785-A1	10-06-2005	Engle et al.		
9.	US-2005/0226844-A1	10-13-2005	Jones		
10.	US-2006/0142229-A1	06-29-2006	Linnik et al.		
11.	US-2006/0217333-A1	09-28-2006	Linnik et al.		
12.	US-2006/0229270-A1	10-12-2006	Linnik		
13.	US-6,858,210-B1	02-22-2005	Marquis et al.		
14.	US-6,951,939-B2	10-04-2005	Jones		
15.	US-7,081,242-B1	07-25-2006	Linnik et al.		
16.	US-7,138,244-B2	11-21-2006	Barstad et al.		

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)			
17.	EP-0 743 856-B1		11-27-1996	The University of Virginia Patent Foundation	
18.	WO-92/05801-A1		04-16-1992	University of Virginia Patents Foundation	
19.	WO-00/15259-A1		03-23-2000	The University of Virginia Patent Foundation	

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
20.	Aharoni, A. et al., (1993) "Characterization of a Multisubunit Human Protein Which Selectively Binds Single Stranded d(GA) _n and d(GT) _n Sequence Repeats in DNA" <i>Nucl. Acid. Res.</i> 21(22):5221-5228.				
21.	Ferguson, P. J. et al. (July 1, 1995). "Antigen-Based Heteropolymers Facilitate, Via Primate Erythrocyte Complement Receptor Type 1, Rapid Erythrocyte Binding of an Autoantibody and Its Clearance From The Circulation in Rhesus Monkeys," <i>The Journal of Immunology</i> 155(1):339-347.				
22.	Food and Drug Administration. (October 13, 2004). Information from United States Food and Drug Administration, 2 pages.				

Examiner Signature	Date Considered
--------------------	-----------------

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
Sheet	2	of	5	Application Number	10/748,541
				Filing Date	December 29, 2003
				First Named Inventor	Vibeke STRAND
				Art Unit	1644
				Examiner Name	G. Ewoldt
				Attorney Docket Number	252312007900

	23.	Iverson, G.M. et al. (December 1998). "Anti- β_2 glycoprotein I (β 2GPI) Autoantibodies Recognize an Epitope on the First Domain of β 2GPI" <i>Proc Natl Acad Sci USA</i> 95:15542-15546.	
	24.	Iverson, G.M. et al. (1998). "A Chemically Defined, Toleragen-Based Approach for Targeting Anti- β_2 -glycoprotein I Antibodies" <i>Lupus</i> 7 (Suppl 2): S166-S169.	
	25.	Jones, D. et al. (1998) "Synthesis of a Cyclic-Thioether Peptide Which Binds Anti-Cardiolipin Antibodies" <i>Tetrahedron Letters</i> 39:6107-6110.	
	26.	Jones, D. et al. (1999). "Multivalent Thioether-Peptide Conjugates: B Cell Tolerance of an Anti-Peptide Immune Response" <i>Bioconjugate Chemistry</i> 10(3):480-488.	
	27.	Jones, D. et al. (2000). "A Convenient Synthesis of N-(tert-butyloxycarbonyl) Aminoxy Ethers," <i>Tetrahedron Letters</i> 41: 1531-1533.	
	28.	Jones, D.S. et al. (1994). "A New Oligonucleotide Conjugate for Suppression of Anti-Double Stranded DNA Antibodies," <i>Abstracts of Papers</i> , Part 1, 207 th American Chemical Society National Meeting, San Diego, CA March 13-17, 1994, Abstract No. BIOT 113.	
	29.	Kandiah, D.A. et al. (1998) "Current Insights into the "Antiphospholipid" Syndrome: Clinical, Immunological, and Molecular Aspects," <i>Advances in Immunology</i> 70:507-563.	
	30.	La Jolla Pharmaceutical Co. (February 16, 2004). "La Jolla Pharmaceutical's New Drug Application for Lupus Drug Candidate Riquent® Accepted for Review by FDA," located at < http://web.archive.org/web/20040919061150/www.prnewswire.com/cgi-bin/stories.pl?ACCT=105&ST... >, last visited on March 26, 2007, 2 pages.	
	31.	La Jolla Pharmaceutical Co. (February 17, 2004). "La Jolla Pharmaceutical's New Drug Application for Lupus Drug Candidate Riquent® Accepted for Review by FDA San Diego," located at < http://www.ljpc.com/pressrelease/0217_04.html >, last visited on April 9, 2007, 2 pages.	
	32.	La Jolla Pharmaceutical Co. (March 2, 2004). "La Jolla Pharmaceutical Company Reports Fourth Quarter and Year End 2003 Financial Results," located at < http://www.ljpc.com/pressrelease/0302_04.html >, last visited on April 9, 2007, 3 pages.	
	33.	La Jolla Pharmaceutical Co. (March 11, 2004). "La Jolla Pharmaceutical to Present Additional Riquent® Results at SG Cowen Healthcare Conference," located at < http://www.ljpc.com/pressrelease/0311_04.html >, last visited on April 9, 2007, 3 pages.	
	34.	La Jolla Pharmaceutical Co. (April 21, 2004). "La Jolla Pharmaceutical to Present at 7 th International Congress on Systemic Lupus Erythematosus and Related Conditions," located at < http://www.ljpc.com/pressrelease/0421_04.html >, last visited on April 9, 2007, 3 pages.	
	35.	La Jolla Pharmaceutical Co. (May 6, 2004). "La Jolla Pharmaceutical Company Reports First Quarter 2004 Financial Results," located at < http://www.ljpc.com/pressrelease/0506_04.html >, last visited on April 9, 2007, 2 pages.	
	36.	La Jolla Pharmaceutical Co. (May 10, 2004). "La Jolla Pharmaceutical Data on Riquent® Presented at Lupus Medical Conference," located at < http://www.ljpc.com/pressrelease/0510_04.html >, last visited on April 9, 2007, 3 pages.	
	37.	La Jolla Pharmaceutical Co. (June 10, 2004). "La Jolla Pharmaceutical Presents at European Rheumatology Medical Conference," located at < http://www.ljpc.com/pressrelease/0610_04.html >, last visited on April 9, 2007, 2 pages.	
	38.	La Jolla Pharmaceutical Co. (June 24, 2004). "La Jolla Pharmaceutical Announces Publication of Review Articles Regarding Its Two Drug Candidates," located at < http://www.ljpc.com/pressrelease/0624_04.html >, last visited on April 9, 2007, 3 pages.	

Examiner Signature		Date Considered
--------------------	--	-----------------

Substitute for form 1449/PTO				Complete if Known	
				Application Number	10/748,541
				Filing Date	December 29, 2003
				First Named Inventor	Vibeke STRAND
				Art Unit	1644
				Examiner Name	G. Ewoldt
Sheet	3	of	5	Attorney Docket Number	252312007900

	39.	La Jolla Pharmaceutical Co. (August 2, 2004). "La Jolla Pharmaceutical Reaches Agreement with Cardio-Renal Division of FDA Regarding Phase 4 Trial Design Under Special Protocol Assessment," San Diego, CA, located at < http://www.ljpc.com/pressrelease/0802_04.html >, last visited on April 9, 2007, 3 pages.	
	40.	La Jolla Pharmaceutical Co. (August 5, 2004). "La Jolla Pharmaceutical Company Reports Second Quarter 2004 Financial Results," located at < http://www.ljpc.com/pressrelease/0805_04.html >, last visited on April 9, 2007, 2 pages.	
	41.	La Jolla Pharmaceutical Co. (October 14, 2004). "La Jolla Pharmaceutical Company Receives Letter From FDA About Riquent," located at < http://www.ljpc.com/pressrelease/1014_04.html >, last visited on April 9, 2007, 2 pages.	
	42.	La Jolla Pharmaceutical Co. (October 29, 2004). "La Jolla Pharmaceutical Company Presents at American College of Rheumatology and American Society of Nephrology Annual Meetings," located at < http://www.ljpc.com/pressrelease/1029_04.html >, last visited on April 9, 2007, 3 pages.	
	43.	La Jolla Pharmaceutical Co. (November 4, 2004). "La Jolla Pharmaceutical Company Reports Third Quarter 2004 Financial Results," located at < http://www.ljpc.com/pressrelease/1104_04.html >, last visited on April 9, 2007, 2 pages.	
	44.	La Jolla Pharmaceutical Co. (November 23, 2004). "La Jolla Pharmaceutical Company Provides Update on Riquent Program," San Diego, CA, located at < http://www.ljpc.com/pressrelease/1123_04.html >, last visited on April 9, 2007, 3 pages.	
	45.	La Jolla Pharmaceutical Co. (February 17, 2005). "La Jolla Pharmaceutical Company Presents at BIO CEO & Investor Conference," located at < http://www.ljpc.com/pressrelease/0217_05.html >, last visited on April 9, 2007, 2 pages.	
	46.	La Jolla Pharmaceutical Co. (March 3, 2005). "La Jolla Pharmaceutical Company Reports Fourth Quarter and Year End 2004 Financial Results," located at < http://www.ljpc.com/pressrelease/0303_05.html >, last visited on April 9, 2007, 2 pages.	
	47.	La Jolla Pharmaceutical Co. (March 14, 2005). "La Jolla Pharmaceutical Announces Outcome of Recent FDA Discussions," San Diego, CA, located at < http://www.ljpc.com/pressrelease/0314_05.html >, last visited on April 9, 2007, 2 pages.	
	48.	La Jolla Pharmaceutical Co. (March 30, 2005). "La Jolla Pharmaceutical Restructures Following Recent FDA Discussion," located at < http://www.ljpc.com/pressrelease/0330_05.html >, last visited on April 9, 2007, 3 pages.	
	49.	La Jolla Pharmaceutical Co. (May 5, 2005). "La Jolla Pharmaceutical Company Reports First Quarter 2005 Financial Results," located at < http://www.ljpc.com/pressrelease/0505_05.html >, last visited on April 9, 2007, 3 pages.	
	50.	La Jolla Pharmaceutical Co. (May 31, 2005). "La Jolla Pharmaceutical Company Provides Update on Riquent," located at < http://www.ljpc.com/pressrelease/0531_05.html >, last visited on April 9, 2007, 2 pages.	
	51.	La Jolla Pharmaceutical Co. (August 4, 2005). "La Jolla Pharmaceutical Company Reports Second Quarter and Year-to-Date 2005 Financial Results," located at < http://www.ljpc.com/pressrelease/0804_05.html >, last visited on April 9, 2007, 3 pages.	
	52.	La Jolla Pharmaceutical Co. (October 13, 2005). "La Jolla Pharmaceutical Company to Present at BIO Investor Forum 2005," located at < http://www.ljpc.com/pressrelease/1013_05.html >, last visited on April 9, 2007, 2 pages.	
	53.	La Jolla Pharmaceutical Co. (October 18, 2005). "La Jolla Pharmaceutical Company Provides Update on Riquent®," located at < http://www.ljpc.com/pressrelease/1018_05.html >, last visited on April 9, 2007, 4 pages.	
	54.	La Jolla Pharmaceutical Co. (November 2, 2005). "La Jolla Pharmaceutical Company Presents at the Rodman & Renshaw Techvest 7 th Annual Healthcare Conference," located at < http://www.ljpc.com/pressrelease/1102_05.html >, last visited on April 9, 2007, 2 pages.	
	55.	La Jolla Pharmaceutical Co. (November 14, 2005). "La Jolla Pharmaceutical Company	

Examiner Signature	Date Considered
--------------------	-----------------

Substitute for form 1449/PTO				<i>Complete if Known</i>	
				Application Number	10/748,541
				Filing Date	December 29, 2003
				First Named Inventor	Vibeke STRAND
				Art Unit	1644
				Examiner Name	G. Ewoldt
Sheet	4	of	5	Attorney Docket Number	252312007900

		Presents at American College of Rheumatology Annual Scientific Meeting," located at <http://www.ljpc.com/pressrelease/1114_05.html>, last visited on April 9, 2007, 3 pages.	
56.		La Jolla Pharmaceutical Co. (January 11, 2006). "La Jolla Pharmaceutical Company to Initiate Multi-Dose Study of Riquent in Lupus Patients," located at <http://www.ljpc.com/pressrelease/0111_06.html>, last visited on April 10, 2007, 2 pages.	
57.		La Jolla Pharmaceutical Co. (March 29, 2006). "La Jolla Pharmaceutical Company Presents at National Autoimmune Disease Conference," located at <http://www.ljpc.com/pressrelease/0329_06.html>, last visited on April 10, 2007, 2 pages.	
58.		La Jolla Pharmaceutical Co. (June 22, 2006). "La Jolla Pharmaceutical Company Files Marketing Authorization Application for European Regulatory Approval of Riquent," located at <http://www.ljpc.com/pressrelease/0622_06.html>, last visited on April 9, 2007, 3 pages.	
59.		La Jolla Pharmaceutical Co. (August 9, 2006). "La Jolla Pharmaceutical Expands Enrollment in Phase 3 International Riquent® Study," located at <http://www.ljpc.com/pressrelease/0809_06.html>, last visited on April 9, 2007, 4 pages.	
60.		La Jolla Pharmaceutical Co. (September 27, 2006). "La Jolla Pharmaceutical Provides Update on Phase 3 International Riquent® Study," located at <http://www.ljpc.com/pressrelease/0927_06.html>, last visited on April 9, 2007, 3 pages.	
61.		La Jolla Pharmaceutical Co. (October 12, 2006). "La Jolla Pharmaceutical Provides Update on MAA Application in Europe," located at <http://www.ljpc.com/pressrelease/1012_06.html>, last visited on April 9, 2007, 3 pages.	
62.		La Jolla Pharmaceutical Co. (November 6, 2006). "La Jolla Pharmaceutical Announces Continued Progress With Phase 3 International Riquent® Study," located at <http://www.ljpc.com/pressrelease/1106_06.html>, last visited on April 9, 2007, 3 pages.	
63.		La Jolla Pharmaceutical Co. (February 1, 2007). "La Jolla Pharmaceutical Announces Continued Enrollment Progress and Enhancements to International Phase 3 Riquent® Study," located at <http://www.ljpc.com/pressrelease/0201_07.html>, last visited on April 9, 2007, 3 pages.	
64.		La Jolla Pharmaceutical Co. (March 8, 2007). "La Jolla Pharmaceutical Announces Positive Interim Antibody Results From Riquent® Lupus Phase 3 Trial," located at <http://www.ljpc.com/pressrelease/0308_07.html>, last visited on April 9, 2007, 4 pages.	
65.		La Jolla Pharmaceutical Co. (March 20, 2007). "La Jolla Pharmaceutical Announces Positive Interim Antibody Results From Riquent® Lupus Phase 3 Trial," located at <http://www.ljpc.com/pressrelease/0320_07_phase_3_results.html>, last visited on April 9, 2007, 3 pages.	
66.		Linnik, M.D. et al. (2004). "Anti-dsDNA Antibodies and Exacerbation of Renal Disease in Patients with Systemic Lupus Erythematosus: Results From 2 Randomized Controlled Trials [RCTS] with LJP 394," located at <http://www.ljpc.com/abstracts/abstract_2004_15.html>, last visited on August 19, 2005, 2 pages.	
67.		Linnik, M.D. et al. (2005). "Progressive Reduction in Risk of Renal Flare in SLE Patients is Associated With Improved Long-term Control of Anti-dsDNA Antibody Levels," located at <http://www.ljpc.com/abstracts/abstract_2005_05.html>, last visited July 29, 2007, 2 pages.	
68.		Linnik, M.D. et al. (April 2005). "Relationship Between Anti-Double-Stranded DNA Antibodies and Exacerbation of Renal Disease in Patients With Systemic Lupus Erythematosus," <i>Arthritis & Rheumatism</i> 52(4):1129-1137.	

Examiner Signature	Date Considered
--------------------	-----------------

Substitute for form 1449/PTO				<i>Complete if Known</i>	
				Application Number	10/748,541
				Filing Date	December 29, 2003
				First Named Inventor	Vibeke STRAND
				Art Unit	1644
				Examiner Name	G. Ewoldt
Sheet	5	of	5	Attorney Docket Number	252312007900

69.	Morimoto, C. et al. (March 1987). "A Defect of Immunoregulatory T Cell Subsets in Systematic Lupus Erythematosus Patients Demonstrated with Anti-2H4 Antibody," <i>J Clin Invest.</i> 79(3):762-768.	
70.	Office Action mailed on February 22, 2005 for U.S. Patent Application No. 10/219,238, 13 pages.	
71.	Office Action mailed on February 26, 2007 for U.S. Patent Application No. 10/814,555, 9 pages.	
72.	Office Action mailed on January 14, 2005 for U.S. Patent Application No. 10/144,391, 11 pages.	
73.	Office Action mailed on July 18, 2000 for U.S. Patent Application No. 09/457,875, 7 pages.	
74.	Office Action mailed on October 5, 2001 for U.S. Patent Application No. 09/766,365, 5 pages.	
75.	PDRhealth. (Date Unknown). "Lupus Erythematosus," located at < http://www.pdrhealth.com/patient_education/BHG01RH18.shtml >, last visited July 11, 2007, 8 pages.	
76.	Sem, D.S. et al. (1998). "Structural Characterization and Optimization of Antibody-Selected Phage Library Mimotopes of an Antigen Associated with Autoimmune Recurrent Thrombosis," <i>Biochemistry</i> 37(46):16069-16081.	
77.	United States Application No. 09/590,592 filed on June 8, 2000 for Jones et al.	
78.	United States Application No. 11/562,174 filed on November 21, 2006 for Strand et al.	
79.	United States Application No. 11/565,467 filed on November 30, 2006 for Linnik et al.	
80.	United States Application No. 11/613,987 filed on December 20, 2006 for Linnik.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--